Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma

References

• Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120:4795–4801.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116:3843–3851.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15:1587–1594.
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126:851–857.
   PubMed Web of Science ®Google Scholar
• Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272–3278.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619–627.
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169–1176.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Galli F, Greene WC, et al. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine. 1990;2:330–336.
   PubMedGoogle Scholar
• Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–1640.
   PubMed Web of Science ®Google Scholar
• Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19:6812–6819.
   PubMed Web of Science ®Google Scholar
• Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol. 2005;131:73–79.
   PubMed Web of Science ®Google Scholar
• Oki Y, Kato H, Matsuo K, et al. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma. 2008;49:1345–1351.
   PubMed Web of Science ®Google Scholar
• Morito T, Fujihara M, Asaoku H, et al. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci. 2009;100:1255–1260.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Yokoyama M, Terui Y, et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol. 2009;20:526–533.
   PubMed Web of Science ®Google Scholar
• Shiratori S, Kosugi-Kanaya M, Shigematsu A, et al. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2015;56:2592–2597.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Maurer MJ, Stenson MJ, et al. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol. 2014;89:E223–E227.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Nannya Y, Imai Y, et al. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:410–416.
   PubMed Web of Science ®Google Scholar
• Prochazka V, Papajik T, Faber E, et al. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Leuk Lymphoma. 2014;55:1584–1590.
   PubMed Web of Science ®Google Scholar
• Mir MA, Maurer MJ, Ziesmer SC, et al. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood. 2015;125:992–998.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Muroi K, Tatara R, et al. Clinical features of de novo CD25-positive follicular lymphoma. Leuk Lymphoma. 2014;55:307–313.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Hubbard SM, Chabner BA, de Vita VT Jr., et al. Histologic progression in non-Hodgkin’s lymphoma. Blood. 1982;59:258–264.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood. 2011;118:2809–2820.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108: 2957–2964.
   PubMed Web of Science ®Google Scholar
• Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115: 289–295.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Feugier P, Offner F, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood. 2013;122:509–509.
   Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424–435.
   PubMed Web of Science ®Google Scholar